Premenopausal insulin-like growth factor-I serum levels and changes in breast density over menopause

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 3, 2007, Pages 451-457

  Verheus, Martijn ^a   Peeters, Petra H M ^a   Kaaks, Rudolf ^b   Van Noord, Paulus A H ^a   Grobbee, Diederick E ^a   Van Gils, Carla H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LINEAR MODELS; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; PREMENOPAUSE; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 34047249577     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0642     Document Type: Article

References (48)

1. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 2001;154:163-9.
2. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
3. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
4. Van Gils CH, Hendriks JH, Holland R, et al. Changes in mammographic breast density and concomitant changes in breast cancer risk. Eur J Cancer Prev 1999;8:509-15.
5. Kleinberg DL. Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998;47:201-8.
6. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998;47:209-17.
7. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49:415-21.
8. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
9. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
10. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
11. Krajcik RA, Borofsky ND, Massardo S, et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566-73.
12. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
13. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3, and breast cancer risk. Br J Cancer 2005;92:1283-7.
14. Schernhammer ES, Holly JM, Pollak MN, et al. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
15. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-16.
16. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3, and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006;13:593-605.
17. Schernhammer ES, Holly JM, Hunter DJ, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006;13:583-92.
18. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003;106:90-5.
19. Gronbaek H, Flyvbjerg A, Mellemkjaer L, et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1759-64.
20. Byrne C, Colditz GA, Willett WC, et al. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
21. Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 2003;107:991-6.
22. Lai JH, Vesprini D, Zhang W, et al. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 2004;13:573-82.
23. Diorio C, Pollak M, Byrne C, et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 2005;14:1065-73.
24. dos Santos Silva I, Johnson N, De Stavola B, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:449-55.
25. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.
26. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001;10:243-8.
27. Boyd N, Martin L, Stone J, et al. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 2002;11:1048-53.
28. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
29. Rollison DE, Newschaffer CJ, Tao Y, et al. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006;118:1279-84.
30. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26 Suppl 1:S6-14.
31. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
32. Boker LK, Van Noord PA, van der Schouw YT, et al. Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. Eur J Epidemiol 2001;17:1047-53.
33. Ocke MC, Bueno-de-Mesquita HB, Pols MA, et al. The Dutch EPIC food frequency questionnaire. II. Relative validity and reproducibility for nutrients. Int J Epidemiol 1997;26 Suppl 1:S49-58.
34. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, et al. The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. Int J Epidemiol 1997;26 Suppl 1:S37-48.
35. Byng JW, Boyd NF, Little L, et al. Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 1996;5:319-27.
36. Byng JW, Boyd NF, Fishell E, et al. The quantitative analysis of mammographic densities. Phys Med Biol 1994;39:1629-38.
37. Trichopoulos D, Lipman RD. Mammary gland mass and breast cancer risk. Epidemiology 1992;3:523-6.
38. Albanes D, Winick M. Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst 1988;80:772-4.
39. Haars G, Van Noord PA, Van Gils CH, et al. Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 2005;14:2634-40.
40. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 2003;35:726-33.
41. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299-307.
42. Djurhuus CB, Gravholt CH, Nielsen S, et al. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 2004;286:E488-94.
43. Louveau I, Gondret F. Regulation of development and metabolism of adipose tissue by growth hormone and the insulin-like growth factor system. Domest Anim Endocrinol 2004;27:241-55.
44. Flint DJ, Binart N, Kopchick J, et al. Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 2003;6:97-102.
45. Hansen TK, Gravholt CH, ORskov H, et al. Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 2002;87:4691-8.
46. Moller N, Gjedsted J, Gormsen L, et al. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 2003;13 Suppl A:S18-21.
47. Mulhall C, Hegele RA, Cao H, et al. Pituitary growth hormone and growth hormone-releasing hormone receptor genes and associations with mammographic measures and serum growth hormone. Cancer Epidemiol Biomarkers Prev 2005;14:2648-54.
48. van Engeland S, Snoeren PR, Huisman H, et al. Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging 2006;25:273-82.